1.All of the following bacteria were identified by the World Health Organization as critical priority pathogens except:

Methicillin-resistant S. aureus

Carbapenem-resistant P. aeruginosa

Carbapenem-resistant A. baumannii

Carbapenem-resistant, ESBL-producing Enterobacteriaceae

2.Which of the following antimicrobials would be the most appropriate choice to treat a 63-year-old man with an infection caused by meropenem-resistant P. aeruginosa?

Imipenem

Ceftolozane-tazobactam

Ampicillin-sulbactam

Meropenem-vaborbactam

3.Newer beta-lactam/beta-lactamase inhibitor agents (i.e., ceftolozane-tazobactam, ceftazidime-avibactam) exhibit activity against all of the following resistant organisms except:

ESBL-producing K. pneumoniae

Fluoroquinolone-resistant E. coli

Metallo-beta-lactamase-producing K. pneumoniae

Multidrug-resistant P. aeruginosa

4.For which of the following patients would be the most appropriate use of bezlotoxumab?

As prophylaxis for a 45-year-old woman undergoing a stem cell transplantation with no history of CDI

As primary treatment for a 67-year-old man with an initial CDI episode

As primary treatment for a 79-year-old man with a second episode of CDI in the past 5 weeks

Combined with standard of care for a 57-year-old woman with 3 episodes of CDI in the past 2 months

5.According to the latest IDSA/SHEA C. difficile guidelines, which of the following would be appropriate treatment of a severe initial episode of CDI?

Vancomycin

Fidaxomicin

Fecal microbiota transplantation

Either vancomycin or fidaxomicin

6.According to the latest IDSA/SHEA C. difficile guidelines, which of the following would not be an appropriate choice for the treatment of a patient with multiple recurrences of CDI?

Metronidazole

Vancomycin

Fidaxomicin

Fecal microbiota transplantation